Literature DB >> 25413630

Breast cancer prevention.

David M Euhus1, Jennifer Diaz.   

Abstract

Breast cancer is the most common cancer in women with 232,670 new cases estimated in the USA for 2014. Approaches for reducing breast cancer risk include lifestyle modification, chemoprevention, and prophylactic surgery. Lifestyle modification has a variety of health benefits with few associated risks and is appropriate for all women regardless of breast cancer risk. Chemoprevention options have expanded rapidly, but most are directed at estrogen receptor positive breast cancer and uptake is low. Prophylactic surgery introduces significant additional risks of its own and is generally reserved for the highest risk women.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast neoplasms; chemoprevention; lifestyle; prophylactic surgery; tamoxifen

Mesh:

Substances:

Year:  2014        PMID: 25413630     DOI: 10.1111/tbj.12352

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  5 in total

1.  Risk-reducing medications for primary breast cancer: a network meta-analysis.

Authors:  Simone Mocellin; Annabel Goodwin; Sandro Pasquali
Journal:  Cochrane Database Syst Rev       Date:  2019-04-29

2.  Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.

Authors:  Jennifer G McIntosh; Jesse Minshall; Sibel Saya; Adrian Bickerstaffe; Nadira Hewabandu; Ashleigh Qama; Jon D Emery
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

Review 3.  Prophylactic mastectomy for the prevention of breast cancer: Review of the literature.

Authors:  Rawan K Alaofi; Mohammed O Nassif; Marwan R Al-Hajeili
Journal:  Avicenna J Med       Date:  2018 Jul-Sep

4.  Implant-based Breast Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Ian J Saldanha; Justin M Broyles; Gaelen P Adam; Wangnan Cao; Monika Reddy Bhuma; Shivani Mehta; Andrea L Pusic; Laura S Dominici; Ethan M Balk
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-03-18

5.  Network-pharmacology-based validation of TAMS/CXCL-1 as key mediator of XIAOPI formula preventing breast cancer development and metastasis.

Authors:  Neng Wang; Yifeng Zheng; Jiangyong Gu; Youli Cai; Shengqi Wang; Fengxue Zhang; Jianping Chen; Honglin Situ; Yi Lin; Zhiyu Wang
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.